Zacks Small Cap Analysis – AZTR: Get Some Pores and skin within the Sport – Model Slux
By John Vandermosten, CFA NYSE:AZTR READ THE FULL AZTR RESEARCH REPORT We’re initiating protection of Azitra, Inc. (NYSE:AZTR) with a goal worth of $4.00 per share. This worth is predicated on our forecasts for the profitable growth and commercialization of ATR-12 for Netherton syndrome (NS). NS is a genetic uncommon illness that impacts the pores … Read more